News articles about Iovance Biotherapeutics (NASDAQ:IOVA) have trended somewhat positive on Sunday, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Iovance Biotherapeutics earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.6388169017058 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research cut Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a report on Thursday. BidaskClub cut Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 22nd. Oppenheimer restated a “buy” rating and issued a $13.00 price target on shares of Iovance Biotherapeutics in a report on Tuesday, September 26th. B. Riley reiterated a “buy” rating and set a $18.00 target price on shares of Iovance Biotherapeutics in a report on Monday, November 13th. Finally, FBR & Co reiterated a “buy” rating and set a $17.50 target price on shares of Iovance Biotherapeutics in a report on Wednesday, October 25th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $14.61.

Shares of Iovance Biotherapeutics (IOVA) traded up $0.20 during trading hours on Friday, reaching $8.35. The company’s stock had a trading volume of 279,657 shares, compared to its average volume of 547,060. The firm has a market cap of $606.49, a PE ratio of -6.42 and a beta of 4.56. Iovance Biotherapeutics has a 52-week low of $4.45 and a 52-week high of $9.54.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). equities research analysts anticipate that Iovance Biotherapeutics will post -1.37 EPS for the current fiscal year.

WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/iovance-biotherapeutics-iova-receiving-somewhat-positive-press-coverage-analysis-finds/1797966.html.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Insider Buying and Selling by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.